Showing results (11-20 of 57) with videos related to
Sort By:
Pageof 6
Frontiers in Oncology|November 7, 2022
MDM2 inhibitors-mediated disruption of mitochondrial metabolism: A novel therapeutic strategy for retinoblastomaArianna Romani, Enrico Zauli, Giorgio Zauli, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2010
The oncogene DEK promotes leukemic cell survival and is downregulated by both Nutlin-3 and chlorambucil in B-chronic lymphocytic leukemic cellsPaola Secchiero, Rebecca Voltan, Maria Grazia di Iasio, et al.International Journal of Molecular Sciences|March 28, 2026
Hyperglycemia-Induced Endothelial Dysfunction: From Classical Pathogenetic Mechanisms to Emerging Insights into ACE2 Protective ActionGiada Lodi, Domenico Sergi, Anna Dipinto, et al.Journal of Cellular Physiology|July 7, 2011
Activation of the p53 pathway induces α-smooth muscle actin expression in both myeloid leukemic cells and normal macrophagesPaola Secchiero, Erika Rimondi, Maria Grazia di Iasio, et al.Investigational New Drugs|October 19, 2010
Anti-leukemic activity of dasatinib in both p53(wild-type) and p53(mutated) B malignant cellsRaffaella Bosco, Marco Rabusin, Rebecca Voltan, et al.Molecules (Basel, Switzerland)|November 13, 2021
Anticancer Activity of Aqueous Extracts from <i>Asparagus officinalis</i> L. Byproduct on Breast Cancer CellsArianna Romani, Fabio Casciano, Claudia Stevanin, et al.Nanoscale|July 16, 2013
Proper design of silica nanoparticles combines high brightness, lack of cytotoxicity and efficient cell endocytosisEnrico Rampazzo, Rebecca Voltan, Luca Petrizza, et al.Molecules (Basel, Switzerland)|October 16, 2025
Multi-Step Synthesis of Chimeric Nutlin-DCA Compounds Targeting Dual Pathways for Treatment of CancerDavide Illuminati, Rebecca Foschi, Paolo Marchetti, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 4, 2011
miR-34a induces the downregulation of both E2F1 and B-Myb oncogenes in leukemic cellsGiorgio Zauli, Rebecca Voltan, Maria Grazia di Iasio, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 2010
Dasatinib plus Nutlin-3 shows synergistic antileukemic activity in both p53 wild-type and p53 mutated B chronic lymphocytic leukemias by inhibiting the Akt pathwayGiorgio Zauli, Rebecca Voltan, Raffaella Bosco, et al.Pageof 6